Long-term classification stability and treatment patterns of inflammatory bowel disease unclassified: a longitudinal observational study - Summary - MDSpire
Advertisement
Long-term classification stability and treatment patterns of inflammatory bowel disease unclassified: a longitudinal observational study
To describe the long-term natural history and treatment patterns in patients with Inflammatory Bowel Disease Unclassified (IBD-U).
Approach:
Study Design: Retrospective analysis based on the Leeds IBD Steroid Study, including adult patients with IBD-U from January 2016 to December 2017.
Patient Comparison: Baseline demographics and treatment patterns of patients with IBD-U were compared with those of ulcerative colitis (UC) and Crohn’s disease (CD).
Follow-Up: Longitudinal follow-up until 2025 to assess the stability of the IBD-U diagnosis.
Key Findings:
52% of the 153 patients with IBD-U were male, with a mean age of 46.6 years and mean disease duration of 13.1 years.
Patients with IBD-U were less likely to receive mesalazine (85%) compared to UC (92%, p=0.0058) but more likely than CD (44%, p<0.0001).
Biologics were used more frequently in IBD-U (21%) than UC (9.5%, p<0.0001) but less than CD (51%, p<0.0001).
Higher steroid use and healthcare resource utilization were noted in IBD-U compared to UC and CD.
At the end of follow-up, 88.2% of patients remained classified as IBD-U.
Interpretation:
Limitations:
The study is retrospective and may be subject to biases inherent in such designs.
Findings are based on a single tertiary center, which may limit generalizability.
